Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 10 of 10 for “"GlaxoSmithKline"”.
-
In‐Vitro Comparison of Tensile Bond Strength of Denture Adhesives on Denture Bases
… Fixodent (Proctor & Gamble™), Super Poligrip (GlaxoSmithKline™), Effergrip (Prestige Brands, Inc.™), and SeaBond (Combe™) were tested with the Instron testing machine on three denture base resin cylinder models fabricated from two heat‐polymerized (Lucitone 199 and SR Ivocap) and one visible …
-
A Systems Biology Approach to Microbiology and Cancer
… which were initiated when I was a co-op at GlaxoSmithKline, are discussed in this thesis. First, next generation sequencing data generated for a phase I clinical trial is analyzed to determine the altered microbial community in human gut before and after antibiotic usage (Chapter 2). To our …
-
Studies Toward the Syntheses of Antiarrythmic, Anti-Virulence, and Anticancer Small Molecules
… this project are currently being investigated by GlaxoSmithKline as anti-virulence agents. Studies toward a biomimetic total synthesis of nigricanoside A: Nigricanoside A, a novel ether-linked glycoglycerolipid with 7 unassigned stereocenters, was reported to possess potent (IC50 ≈ 3 nM) …
-
The Physical Chemistry of pMDI Formulations Derived from Hydrofluoroalkane Propellants. A Study of the Physical Behaviour of Poorly Soluble Active Pharmaceutical Ingredients; Bespoke Analytical Method Development Leading to Novel Formulation Approaches for Product Development.
… co-deposition (Seretide® / Symbicort®, GlaxoSmithKline / AstraZeneca). In combination, these methods provide a platform for development of new formulations based on HFA propellants. The methods have been applied to a number of ‘real’ systems incorporating derivatised cyclodextrins and …
-
The development of small molecule inhibitors for fibrosis drug discovery
… role in the pathogenesis. In collaboration with GlaxoSmithKline, the projects detailed in this report were aimed to develop small molecule inhibitors with drug like physicochemical properties for fibrosis drugdiscovery.;Chapter 1 focusses on the secreted enzyme ATX, which is responsible for the …
-
Understanding and optimisation of non-conventional emulsions
… containing them. The project was sponsored by GlaxoSmithKline, a world leading pharmaceutical company, whose interest is in using the knowledge to help in research and development of new products and optimising existing products during manufacture. For this reason pharmaceutical ingredients …
-
I. Development of three-component alkene carboamination reactions II. Palladium-catalyzed anti-Markovnikov oxidative amination of alkenes III. Chloroform as a carbon monoxide precursor: in or ex situ generation of co for pd-catalyzed carbonylations IV. Hydroalkylation of alkenes via photoredox catalysis
… candidates synthesized between 2008 and 2011 by GlaxoSmithKline, Pfizer, and AstraZeneca, 80% of compounds contain at least one amine and 65% of compounds feature amide moieties. In a separate analysis it was found that 84% of structurally unique small-molecule drugs approved by the Food and Drug …
-
Construcción de una marca exitosa de medicamento de venta libre
Al momento de pensar en construir una marca de medicamento bajo la condición de venta libre, se tiende a pensar que su dinámica es similar a cualquier marca de consumo masivo. Los laboratorios toman sus productos y piensan que con solo publicidad lograrán imponer sus marcas en un mercado saturado …
-
Membrane permeation from solutions, particle dispersions and particle-stabilised emulsions
… (CASE) award with an additional sponsorship by GlaxoSmithKline (GSK). The interest of GSK in this research is in the understanding of how the various types of topical formulation available, such as solutions, ointments, dispersions and emulsions, influence the characteristics of drug transport …
-
Design, synthesis, and structure-activity relationship studies of dual Plasmodium falciparum phosphatidylinositol 4-kinase and cGMP-dependent protein kinase inhibitors
… inhibitor for malaria. MLN0128 was identified by GlaxoSmithKline (GSK) Cellzome facility as a Plasmodium multi-kinase inhibitor with potent PI4K and PKG inhibitory activity. In this study, an in silico-guided structural modification strategy was undertaken towards optimizing dual Plasmodium kinase …